Akero Therapeutics/$AKRO
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Akero Therapeutics
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.
Ticker
$AKRO
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
69
ISIN
US00973Y1082
Website
AKRO Metrics
BasicAdvanced
$4.4B
-
-$3.74
-0.13
-
Price and volume
Market cap
$4.4B
Beta
-0.13
52-week high
$58.40
52-week low
$21.02
Average daily volume
1.9M
Financial strength
Current ratio
16.804
Quick ratio
16.171
Long term debt to equity
2.7
Total debt to equity
2.727
Interest coverage (TTM)
-63.41%
Profitability
EBITDA (TTM)
-306.33
Management effectiveness
Return on assets (TTM)
-18.52%
Return on equity (TTM)
-27.92%
Valuation
Price to book
4.04
Price to tangible book (TTM)
4.04
Price to free cash flow (TTM)
-14.988
Free cash flow yield (TTM)
-6.67%
Free cash flow per share (TTM)
-366.29%
Growth
Earnings per share change (TTM)
16.23%
3-year earnings per share growth (CAGR)
5.35%
What the Analysts think about AKRO
Analyst ratings (Buy, Hold, Sell) for Akero Therapeutics stock.
Bulls say / Bears say
Wolfe Research initiated coverage on Akero Therapeutics with an 'Outperform' rating and a $40 price target, citing the potential of its NASH treatment, efruxifermin (EFX), and estimating peak revenues of approximately $3 billion by 2040. (investing.com)
Akero Therapeutics announced the pricing of an upsized public offering, raising approximately $350 million, which is expected to support the advancement of its clinical programs. (tradingview.com)
Analysts have set a consensus price target of $76.29 for Akero Therapeutics, indicating strong confidence in the company's future performance. (americanbankingnews.com)
Akero Therapeutics' stock plummeted 67% after its NASH treatment, efruxifermin, missed the primary endpoint in a mid-stage trial, raising concerns about its efficacy. (schaeffersresearch.com)
The company's CFO sold shares worth over $4.3 million, which could be perceived as a lack of confidence in the company's near-term prospects. (investing.com)
ALKEON CAPITAL MANAGEMENT LLC reduced its stake in Akero Therapeutics, possibly indicating diminished confidence from institutional investors. (gurufocus.com)
Data summarised monthly by Lightyear AI. Last updated on 4 Jun 2025.
AKRO Financial Performance
Revenues and expenses
AKRO Earnings Performance
Company profitability
AKRO News
AllArticlesVideos
Bronstein, Gewirtz & Grossman, LLC Encourages Akero Therapeutics, Inc. (AKRO) Shareholders to Inquire about Securities Investigation
Accesswire·2 weeks ago
Bronstein, Gewirtz & Grossman, LLC Is Investigating Akero Therapeutics, Inc. (AKRO) And Encourages Shareholders to Connect
Accesswire·2 weeks ago
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Akero Therapeutics, Inc. (AKRO) And Encourages Shareholders to Reach Out
Accesswire·2 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Akero Therapeutics stock?
Akero Therapeutics (AKRO) has a market cap of $4.4B as of June 20, 2025.
What is the P/E ratio for Akero Therapeutics stock?
The price to earnings (P/E) ratio for Akero Therapeutics (AKRO) stock is 0 as of June 20, 2025.
Does Akero Therapeutics stock pay dividends?
No, Akero Therapeutics (AKRO) stock does not pay dividends to its shareholders as of June 20, 2025.
When is the next Akero Therapeutics dividend payment date?
Akero Therapeutics (AKRO) stock does not pay dividends to its shareholders.
What is the beta indicator for Akero Therapeutics?
Akero Therapeutics (AKRO) has a beta rating of -0.13. This means that it has an inverse relation to market volatility.